Biosignature Predicts Benefit of Adjuvant Radiotherapy in Patients With DCIS

episode

Cleveland Clinic Cancer Advances not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Morgan Stanley email exposes deal secrets 3 min · 23 Sep 2026 · Wall Street Breakfast

Win Brooke's Bucks (9/23/26) 7 min · 23 Sep 2026 · Brooke and Jeffrey

2026-09-23- KSR - Hour 2 51 min · 23 Sep 2026 · KSR

Kevin Harlan Is As Good As Anyone In Football | Hour 2 36 min · 23 Sep 2026 · The Dan Le Batard Show

12PM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

2026-09-23- KSR - Hour 1 51 min · 23 Sep 2026 · KSR

Report any issue

Source

Recorded16 Dec 2021

Publisherfeeds.buzzsprout.com

Handlerec:1648299

Show notes

Results from a multi-institutional study led by a Cleveland Clinic researcher, DCSionRT®, a biosignature based on multiple biomarkers, may hold the key to solving the treatment of ductal carcinoma in situ (DCIS). Chirag Shah, MD, coinvestigator, and director of Breast Radiation Oncology at Cleveland Clinic joins the Cancer Advances podcast to explain the study and findings that were presented at the American Society for Radiation Oncology annual meeting (ASTRO).

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in